AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT06284122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vincristin
Description: 1.4 mg/m2 (cap cf. below)$ Day 1 from C1 to C6
Study NCT05388435 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SKL27969
Description: SKL27969 will be orally administered once daily on an intermittent dosing schedule (3 days on and 4 days off).
Study NCT06284122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Prednisone
Description: 100 mg/day Day 1 to Day 5 from C1 to C6
Study NCT06121180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ZIV-Aflibercept
Description: Ziv-Aflibercept is an investigational or experimental anti-cancer agent inactivates vascular endothelial growth factor (VEGF) from functioning and scientific experiments have shown that when VEGF is prevented from working, new blood vessels don't form in tumors and these tumors do not grow. In addition, VEGF has been shown to have a negative effect on the immune response and blocking it may help the immune response against cancer.
Study NCT06121180 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemiplimab
Description: Cemiplimab is a human monoclonal anti-PD-1 antibody that works by blocking the programmed death-1 (PD-1), a cell receptor on immune cells that is involved in preventing immune cells from destroying other cells.~Blocking the receptor is expected to help immune cells attack cancer cells.
Study NCT05520099 — intervention group
Intervention type: PROCEDURE
Intervention: Core Needle or Forceps Biopsy
Description: Subjects must be clinically able, at investigator discretion, to undergo additional core needle or forceps biopsy passes during their biopsy. These additional biopsies may either be collected from the primary tumor or a metastatic site amenable to additional passes (e.g., liver or lymph nodes) per the clinician.
Study NCT06239831 — intervention group
Intervention type: DEVICE
Intervention: ExSpiron and ActivPAL Monitors
Description: ExSpiron chest monitor will be placed on the chest ActivPAL accelerometer will be placed on the chest and thigh
Study NCT04655495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low FODMAPs /balanced gluten free diet
Description: Dietary Supplement: Balanced low FODMAPs /gluten free diet
Study NCT04655495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Low FODMAPs /balanced gluten free diet
Description: Dietary Supplement: Balanced low FODMAPs /gluten free diet
Study NCT06284122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: when associated to bendamustin IV 375mg/m² SC 1400 mg allowed from C2 Day 1 of C1 Day 1 from C2 to C6 Day 1 from C7 to C18
Study NCT06284122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Obinutuzumab
Description: when associated to bendamustin 1000 mg Day 1, Day 8, Day 15 of C1 Day 1 from C2 to C8 Day 1 from C9 to C20
Study NCT06284122 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bendamustin
Description: 90 mg/m2 Day 1 and Day 2 from C1 to C6
Study NCT06478758 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ibuprofen 400 mg
Description: The ibuprofen group (n=36) was administered 800 mg of ibuprofen . All procedures were performed with the same team. During surgery, a 20% increase in the participant's heart rate and mean arterial pressure remifentanil infusion was administered. During the postoperative period, all participants continued to receive acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4. In the recovery room, the participants with a visual analog score of > 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of > 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.
Study NCT06478758 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acetaminophen 100 MG/ML
Description: The investigators administered 1000 mg of acetaminophen to the participants in Group A. A 20% increase in the participant's heart rate and mean arterial pressure was evaluated as pain and remifentanil infusion was administered. All participants continued to receive the routine application of acetaminophen at 8-hour intervals, and tramadol was given to those with a visual analog score above 4, postoperatively.In the recovery room, participants with a visual analog score of > 4 were administered 100 mg of tramadol. All participants were prescribed acetaminophen every 8 hours postoperatively in whilst on the ward. Participants with a visual analog score of > 4 received rescue analgesia with 100 mg of tramadol. Visual analog score and vital parameters were recorded at 1, 2, 6, 12 and 24 h postoperatively. The incidence of nausea and vomiting during the 24 h postoperative period was also recorded.
Study NCT06459778 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Piezo-ICSI
Description: Participants had their oocytes cohort divided, where half were injected using conventional ICSI and the other half were injected using Piezo-ICSI.
Study NCT05196620 — intervention group
Intervention type: OTHER
Intervention: Endoanal Ultrasound (EAUS)
Description: Endoanal Ultrasound pre- and postpartum
Study NCT05838248 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: antibiotic duration
Description: Duration of antibiotic treatment post appendectomy
Study NCT04341194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-driven pain management with skin-to-skin contact
Description: The infant is placed naked (except for a diaper and possibly a hat) on the parents' bare chest.
Study NCT04341194 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-driven pain management with skin-to-skin contact/breastfeeding/parental singing
Description: Live parental infant-directed lullaby singing is an individually tailored, non-verbal, multisensory, multimodal and affective tool to regulate the infant before, during and after venipuncture. Direct breast-feeding has demonstrated efficacy that is equal to, or greater than, sweet taste interventions in reducing behavioral and physiological responses to pain in full-term infants undergoing venipuncture with no demonstrated adverse outcomes. Direct breast-feeding should be considered the preferred first-line analgesic intervention for painful procedures performed on full-term infants.
Study NCT04883580 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Navigation and Positioning System for Orthopedic Surgeries
Description: Experimental group: orthopedic surgery navigation system (Tuodao) assisted pedicle screw fixation~Control group: orthopedic surgery navigation system (tianzhihang) assisted pedicle screw fixation
Study NCT04883580 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Navigation and Positioning System for Orthopedic Surgeries
Description: Experimental group: orthopedic surgery navigation system (Tuodao) assisted pedicle screw fixation~Control group: orthopedic surgery navigation system (tianzhihang) assisted pedicle screw fixation
Study NCT06295081 — intervention group
Intervention type: OTHER
Intervention: Exercise exposure
Description: Exercise is NOT part of our study protocol. Participants will voluntarily participate in a mass-participation exercise event (i.e. walking, cycling or running). Participation in this exercise event is voluntary and independent from participation in this study (i.e. participants would also take part in the exercise event if they did not participate in our study). Therefore, we do not consider the performed exercise an intervention or part of our study protocol. Hence, we consider our study design to be observational.~Participants will perform exercise during a mass-participation exercise event, stratified for type of exercise (walking versus running versus cycling; n=500 each).~The mass-participation exercise events have a sport-specific minimum distance of:~a mass-participation exercise event with a:~* Walking distance ≥20 km~* Cycling distance ≥100 km~* Running distance ≥15 km
Study NCT05874401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trilaciclib
Description: Participants will receive intravenous trilaciclib infusion
Study NCT05874401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive intravenous placebo infusion
Study NCT05874401 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Topotecan
Description: Participants will receive intravenous topotecan infusion
Study NCT05874401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topotecan
Description: Participants will receive intravenous topotecan infusion
Study NCT06554314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: probiotics
Description: Eat a capsule for once, and once a day
Study NCT06554314 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: probiotics
Description: Eat a capsule for once, and once a day
Study NCT05819801 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Non-fasting
Description: Instructing patients to eat before their local-only procedure
Study NCT05819801 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fasting
Description: Instructing patients to fast before their local-only procedure
Study NCT06493253 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Digital Pathology FibroNest Phenotypic Fibrosis Composite Score (Ph-FCS)
Description: Biomarker name: FibroNest Phenotypic Fibrosis Composite Score Acronym: FibroNest Ph- FCS Type of Biomarker: Histologic based, Digital, Quantitative Image Analysis, Imaging modality Definition: A quantitative, normalized (no unit) and continuous composite
Study NCT05450029 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab
Description: 6 cycles of mFOLFOX6 (oxaliplatin 85 mg/m2, and folinic acid 400 mg/m2 followed by bolus 5-fluorouracil 400 mg/m2 and 5-fluorouracil 2400mg/m2 as a 46-hour continuous infusion on day 1) followed by long course chemoradiotherapy (50 Gy in 25 fractions) followed by surgery. Patients will receive sintilimab 3mg/kg every 2 weeks during chemoradiotherapy (2nd-6th cycle).
Study NCT05603442 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thoracic intervertebral foramen block
Description: The thoracic intervertebral foramen block is performed by placing the needle tip over and behind the transverse process of vertebra, via the thoracic intervertebral foramen.
Study NCT05962775 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Ethanol Sclerotherapy for Endometrioma
Description: 2 gr IV cefazolin sodium will be administered 30 minutes before the procedure. The endometrioma cyst content will be aspirated by a single lumen needle, and the total aspirated volume calculation will be done. The endometrioma will then be washed with saline until the color of the cyst content becomes clear. Then, 96% ethanol will be injected into the cyst. The volume of injected ethanol will be 60% of the first aspirated volume (maximum 100 ml). After 10 minutes all ethanol will be aspirated.
Study NCT06258382 — intervention group
Intervention type: OTHER
Intervention: Questionnaires and functional test
Description: Data will be collected from different sources. Questinnaires, Medical journal, Obstetrical records and functional tests
Study NCT04808635 — intervention group
Intervention type: OTHER
Intervention: no intervention, this is a cross sectional questionnaire based study.
Description: no intervention, this is an observational cross sectional study
Study NCT05511753 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: Insert stainless steel needles into the above acupoints and twist the needles to get qi. In addition, electroacupuncture stimulation (intensity 1mA, frequency 2Hz) was applied to connect the ipsilateral Yifeng and Wangu, and the ipsilateral Zhongzhu and Quchi.
Study NCT05531851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Instrument Assisted Soft Tissue Mobilization
Description: For IASTM treatment, IASTM soft tissue mobilization blade to apply the treatment used. It is a stainless steel shaped metal tool with beveled edges. The researcher, with a 30° angled tool, at a speed of 120 BPM, in the direction of the fibers of the m.biceps brachii muscle.~He applied it with a light pressure by intervening with his weight. Researcher during treatment used a metronome to ensure consistent speed and adjusted the instrument angle before each subject's treatment.~calibrated with a protractor. The application took 8 minutes and the instrument was comfortable on the skin.
Study NCT05790707 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Atrial fibrillation ablation + antiarrhythmic drugs
Description: Atrial fibrillation ablation will be performed with endovascular catheters and will be done either with radiofrequency, cryoballoon or pulsed field ablation.~Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed.
Study NCT05790707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Antiarrhythmic drug
Description: Amiodarone, flecainide, sotalol, propafenone are the anti arrhythmic drugs allowed.
Study NCT04782752 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation: Varying Doses of RT
Description: 3+3 radiation dose escalation model to see the maximum tolerated dose
Study NCT05739734 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CRIS100
Description: local application of CRIS100
Study NCT04661449 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Comprehensive lifestyle intervention
Description: Feeding guidance: promoting exclusive breastfeeding and healthy diet (Pediatrician). Motor development assessment and guidance: Alberta Infant movement scale (AIMS) evaluation, guidance for motor development (Rehabilitation Therapist). Healthcare education: improvement of environmental exposure (Pediatrician).
Study NCT06429514 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Ganoderma lucidum spore powder
Description: One bag at a time, 2 times a day, 2g / bag
Study NCT06429514 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: One bag at a time, 2 times a day, 2g / bag
Study NCT05622994 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Rimonabant
Description: Rimonabant 5mg per day is administered for 90 days. The comparator is placebo for the same duration.
Study NCT05622994 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rimonabant
Description: Rimonabant 5mg per day is administered for 90 days. The comparator is placebo for the same duration.
Study NCT05140317 — intervention group
Intervention type: PROCEDURE
Intervention: Transcatheter heart valve implantation with or withour predilatatation
Description: long term up to 5 years echographic and clinical follow up
Study NCT06474481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zanubrutinib
Description: Zanubrutinib, 160mg PO BID.on days 1-28 Induction treatment: 4-6cycles ; Maintenance: 1 year;
Study NCT06474481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: Induction treatment: Obinutuzumab (G), 1000mg, IV, D1/8/15 (C1), D1 (C2-4/6); for 4-6 cycles, 1 cycle = 28 days Maintenance: Obinutuzumab (G), 1000mg, IV, every 2 months for 1 year;
Study NCT06474481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Prednisone (P), 100 mg, PO, D2-6；for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
Study NCT06474481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Cyclophosphamide (C), 750 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
Study NCT06474481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: Vincristine (O), 1.4 mg/m2 (maximum 2 mg), IV, D2; for 4-6 cycles for CHOP treatment , 1 cycle = 28 days
Study NCT06474481 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: Doxorubicin (H), 50 mg/m2, IV, D2; for 4-6 cycles for CHOP treatment ，1 cycle = 28 days
Study NCT06388109 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Positive Peers mobile app
Description: Positive Peers is a multifunctional mobile app using a mind, body, spirit theme aimed to improve HIV care outcomes.
Study NCT06388109 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Positive Peers mobile app
Description: Positive Peers is a multifunctional mobile app using a mind, body, spirit theme aimed to improve HIV care outcomes.
Study NCT05407519 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab + Sitravatinib
Description: Drug: Tislelizumab Tislelizumab 200mg IV q3w Other Names: BGB-A317, Immunotherapy, Anti-PD-1 antibody Drug: Sitravatinib Sitravatinib 100mg PO qd Other Name: tyrosine kinase inhibitor, TKI
Study NCT03807102 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tumor Vaccine
Description: NeoAntigen Tumor Vaccine (5 injections for each 3 days and then 1 injection for each 3 months till recurrence or up to 2 years).
Study NCT06518837 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tirzepatide
Description: The intervention aims to assess the feasibility, safety, and efficacy of tirzepatide for weight loss in patients with early-stage hormone receptor-positive, HER2-negative breast cancer, potentially improving treatment outcomes and overall health.
Study NCT00104754 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liposomal SN-38
Study NCT04313335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duloxetine
Description: Oral Duloxetine (up to 60 mg per day) will be given, titrated, tapered in accordance with the pain intensity during the acute herpes zoster period.
Study NCT05990660 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JuxtaFlow System
Description: Mild, controlled negative pressure introduced into the renal pelvis via JuxtaFlow catheters
Study NCT06554938 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: water pik
Description: One side of the mouth was flossed with Super Floss® (Oral-B) and the other with Waterpik®.
Study NCT06554938 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Super floss
Description: One side of the mouth was flossed with Super Floss® (Oral-B) and the other with Waterpik®.
Study NCT06263426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV D+/R+
Description: Receipt of kidney transplant from a deceased donor with HIV.
Study NCT06263426 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: HIV D-/R+
Description: Receipt of kidney transplant from a deceased donor without HIV.
Study NCT04093739 — intervention group
Intervention type: DEVICE
Intervention: G7 Freedom Constrained Liners
Description: Patients that have been implanted with the G7 Freedom Constrained Liners to repair hip malfunction and/or disease.
Study NCT06176300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAR - the SEED Method
Description: The SEED Method is an evidence-based Participatory Action Research (PAR) approach that engages youth and adult stakeholders in collective decision-making and action in supporting PYD opportunities in their communities.
Study NCT06176300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PAR-Youth Voices
Description: Youth Voices is a developmentally appropriate and culturally responsive PAR approach designed for African American adolescents. The curriculum relies on frameworks including sociopolitical development (e.g., civic engagement and social justice), racial socialization, and racial identity development. Youth Voices will be implemented in high schools serving the intervention communities.
Study NCT06176300 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Emerging Leaders hospital-based intervention
Description: Emerging Leaders is a violence prevention strategy that provides evidence-based intervention and resources for high-risk youth and their families in the youth's home and community. Emerging Leaders consists of four core components to prevent violence: (1) brief hospital-based violence intervention, (2) 3-months of community case management, (3) an in-home firearm safety counseling program, and (4) an 8-week youth positive development workshop series.
Study NCT01313104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colposcopy
Description: Undergo colposcopy
Study NCT01313104 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cervical Papanicolaou test
Description: Undergo cervical Pap smear
Study NCT01313104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: screening method
Description: Undergo anal Pap smear
Study NCT01313104 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: screening method
Description: Undergo high resolution anoscopy
Study NCT05281601 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD7442
Description: IM Administration: AZD8895 and AZD1061 (comprising AZD7442), must both be administered separately to the participant in a sequential order.~IV Administration: AZD7442 is dosed by co-administration of AZD8895 and AZD1061 in a single IV infusion.
Study NCT05772572 — intervention group
Intervention type: OTHER
Intervention: Questionnaires
Description: Questionnaires are completed only once and assess:~* recorded questions about the disease and the operation for the parents and the patient, human figure drawing test and drawing of the operation for the patient~* psychiatric questionnaires for parents and patients on anxiety and depression~* behavior questionnaires for the parents and the patient: assessment of attachment~* questionnaires for the parents and the patient concerning the family context, the quality of life
Study NCT06380257 — intervention group
Intervention type: OTHER
Intervention: Observational study methods
Description: Neuroimaging, body compostion, laboratory tests and psychiatric interview in study and in control groups.